351 Spam-Free Article(s) Found
Sort:
Date
Filter:
All
Symbol Name Last Close Mkt Cap DailyStocks'
Rating
Our DailyStocks’ Rating System is a proprietary algorithm that combines the vote of the investor community and legendary trader Richard Dennis’ Turtle Trader System and the System Rules of the Turtle Traders Each day, we generate Buy, Sell, Uptrend or Downtrend signals for 3000 Stocks in the U.S. Markets.
Vote Now!
Thursday’s Close
BIOS BioScrip, Inc. $2.99 $382.86M Downtrend
Article Searches
INmune Bio prices IPO at $8 https://seekingalpha.com/news/3423240-inmune-bio-prices-ipo-8?source=feed_news_all Jan 15, 2019 - INmune Bio (INMB) prices its "best efforts" IPO at $8 per share, expecting to raise $8M - 20M depending on demand (1M - 2.5M shares).The company develops immunotherapies that it says harness t
Array Bio up 11% premarket on positive late-stage data on triplet therapy for certain type of colorectal cancer https://seekingalpha.com/news/3423001-array-bio-11-percent-premarket-positive-late-stage-data-triplet-therapy-certain-type?source=feed_news_all Jan 15, 2019 - Array BioPharma (NASDAQ:ARRY) is up 11% premarket on light volume on the heels of its announcement of updated data from a Phase 3 clinical trial, BEACON CRC, evaluating the combination of BRAFTOVI (en
Assembly Bio advancing studies of HBV candidate ABI-H0731; investors unmoved, shares down 17% this week https://seekingalpha.com/news/3422141-assembly-bio-advancing-studies-hbv-candidate-abi-h0731-investors-unmoved-shares-17-percent?source=feed_news_all Jan 10, 2019 - Thinly traded micro cap Assembly Biosciences (ASMB -10%) is down on double normal volume. Shares have retreated 22% since touching the intraday high of $25.68 on Monday and are down 17% for the week.I
Hemispherx Bio up 22% on Ampligen + Keytruda studies https://seekingalpha.com/news/3421524-hemispherx-bio-22-percent-ampligen-keytruda-studies?source=feed_news_all Jan 08, 2019 - Thinly traded nano cap Hemispherx Biopharma (HEB +22.1%) is up on a 7x surge in volume in reaction to its announcement of two clinical trials evaluating the combination of Ampligen (rintatolimod) and
ADMA Bio up 7% on submission of responses to Bivigam CRL https://seekingalpha.com/news/3421023-adma-bio-7-percent-submission-responses-bivigam-crl?source=feed_news_all Jan 07, 2019 - ADMA Biologics (ADMA +7.1%) is up on below-average volume in following its announcement that it has submitted its responses to the CRL it received from the FDA in December 2018 in response to its mark
Alder Bio inks $100M stock sales deal with JPMorgan https://seekingalpha.com/news/3420848-alder-bio-inks-100m-stock-sales-deal-jpmorgan?source=feed_news_all Jan 04, 2019 - Alder BioPharmaceuticals (NASDAQ:ALDR) enters into a $100M at-the-market stock sales agreement with JPMorgan who will earn a 3% commission for its efforts.
Arcus Bio down 14% on COO departure https://seekingalpha.com/news/3420790-arcus-bio-14-percent-coo-departure?source=feed_news_all Jan 04, 2019 - Thinly traded micro cap Arcus Biosciences (RCUS -13.9%) is down on almost double normal, albeit on turnover of only 439K shares, in response to the announced exit of COO and CFO Jennifer Jarrett to &#
Atara Bio up 9% after yesterday's CEO departure-stoked selloff https://seekingalpha.com/news/3420717-atara-bio-9-percent-yesterdays-ceo-departure-stoked-selloff?source=feed_news_all Jan 04, 2019 - Atara Biotherapeutics (ATRA +8.5%) is up on average volume in early trade as buying recovers after yesterday's 19% plummet in reaction to the planned departure of CEO Isaac Ciechanover, M.D.Cheerleade
14 Steps To Writing Great Financial Advisor Bios https://seekingalpha.com/article/4231415-14-steps-writing-great-financial-advisor-bios?source=feed_all_articles Jan 04, 2019 - Your bio is your opening shot at overcoming readers’ ingrained apprehension about financial salespeople. Spend extra time on the opening.Tell your story. This is your first and best chance to humanize
Atara Bio in-licenses CAR-T candidate from Memorial Sloan Kettering https://seekingalpha.com/news/3420456-atara-bio-licenses-car-t-candidate-memorial-sloan-kettering?source=feed_news_all Jan 03, 2019 - Atara Biotherapeutics (ATRA -9%) has exclusively in-licensed a mesothelin-targeted CAR-T therapy from Memorial Sloan Kettering Cancer Center.Mesothelin is a protein that is highly expressed in certain

Pages: 123456...36

Page 1>

Related Companies

Name Exchange Price Mkt Cap
CIVI Civitas Solutions, Inc. NYSE $14.35 $519.89M
CCM Concord Medical Services Holdings Limited NYSE $3.499 $151.73M
PETS PetMed Express, Inc. NASDAQ $36.88 $762.88M
ADUS Addus HomeCare Corporation NASDAQ $68.95 $806.53M
KANG iKang Healthcare Group, Inc. NASDAQ $17.41 $1.21B
Sector: Health Care > Industry: Medical/Nursing Services
DeepLinks for BioScrip
BIOS - Google Finance https://www.google.com/finance?q=BIOS Industry related info and international coverage Summary News
BIOS - Bloomberg http://www.bloomberg.com/research/stocks/snapshot/snapshot.asp?ticker=BIOS Original news and commentary from Bloomberg Charts Financials with pensions Snapshot Earnings Transactions People Options